This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
We have written on the value of a creating a globally diverse REIT portfolio before. For those not wanting to go through the trouble, BPY shares accomplish some of that with a single purchase. It is rare to find a real estate company with a dividend yield over 6% with such a superb portfolio. The built in diversification of office, retail and opportunistic investments along with a global portfolio add to the appeal.
TCO.PRK TCO.PRJ GGP TCO GGP.PRA
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4X(# @;V)J#3P\+TQI;F5A8F)D [email protected]&)@8#H$(ADKP.1Z$,D6 2*9'X)EP2+,?6!2!$P^ [email protected]]D-8%(.1-J: [email protected]"2#20 ALFCJ09.0* :MO!)+_]8'B0'M/@D2 \D. _,_ =/8)0( ! )(Q M#G(-"F5N9'-T
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8S(# @;V)J#3P\+TQI;F5A8F)D [email protected]&)@8%H*(ADKP.02$,EZ"D0R+P3+%H-));#((C!Y%TP>!8L_!;/+0:2M [email protected] D&45.P$W^'[email protected]"-"& 2;_,S!N> 408 #%:1!)#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @(" @ M( T*,3 T(# @;V)J#3P\+T,@,3 X+T9I;'1E
tcosecresponseletter4271 April 27, 2018 VIA EMAIL AND EDGAR Office of Mergers and Acquisitions Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0805 Attention: Daniel F. Duchovny, Esq. and Joseph McCann, Esq., SEC Divis
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
KRC.PRG BPY KRC.PRH DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC JCAP.PRB AVB REG.PRG REG.PRF VNO EQIX TCO.PRK TCO.PRJ FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG DLR.PRH DLR.PRG DLR.PRJ DLR.PRI SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD SPG.PRJ KRLP OFC IRT BXP.PRB REXR DLR LPT DLR.PRC WRI DLR.PRF ESRT
DDR Corp. (DDR - Free Report) recently completed the previously-announced spin-off of a portfolio of 48 properties into a new public company — Retail Value Inc. (“RVI”). RVI will now begin regular-way trading on the NYSE under the ticker symbol of RVI. Its portfolio consists of 36 continental U.S. assets and DDR’s entire Puerto Rico portfolio of 12 assets. Per the press release of RVI, the company has a gross book value of nearly $2.
KIM.PRI DDR ABX TCO.PRK TCO.PRJ TCO KIM.PRM KIM.PRL RVI.WI KIM.PRK KIM.PRJ DDR.PRJ DDR.PRK DDR.PRA DDR.WI KIM MAC ABX
Simon Property Group, Inc. (SPG - Free Report) announced that it will expand the Happy Returns services available at its malls to several other locations. This will enable an increasing number of customers to return purchases made online at malls where Simon Guest Services is available.
KIM.PRI TCO.PRK TCO.PRJ TCO KIM.PRM KIM.PRL KIM.PRK KIM.PRJ SPG.PRJ SPG KIM MAC
The holdings in the ETF are extremely diverse, with the highest weights going to large REITs with strong fundamentals.
REG DLR.PRH KIM.PRI DLR.PRG DLR.PRJ DLR.PRI DRE AMT.PRB STAG.PRB AMT.PRA STAG.PRC TCO KIM.PRM KIM.PRL KIM.PRK KIM.PRJ AMZN AMT ESS CCI.PRA CCI GGP MAC KIM STAG STAG.PRA REG.PRG REG.PRF EQIX TCO.PRK TCO.PRJ DRE.PRO PLD BRX SPG.PRJ T VZ STAG.PRBCL DLR SPG SBAC DLR.PRC WPG DLR.PRF DRE.PRL CBL
Brick-and-mortar retailers are transforming into “brick-and-click” retailers, integrating across digital and physical channels to personalize service.
LOW REG KIM.PRI HD WBA TCO CVS KIM.PRM KIM.PRL WMT KIM.PRK KIM.PRJ KR AMZN KIM REG.PRG REG.PRF TCO.PRK TCO.PRJ ROIC COST NNN.PRD NNN.PRF TGT NNN.PRE NNN
12h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TCO / Taubman Centers, Inc. on message board site Silicon Investor.
as of ET